Catalysts / MPLT
Upcoming FDA decisions and readouts we track for MapLight Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for MapLight Therapeutics (MPLT, listed on Nasdaq). It concerns ML-007C-MA (Alzheimer’s disease psychosis (hallucinations and delusions)).
First on the list: the Phase 2 readout for ML-007C-MA (Alzheimer’s disease psychosis (hallucinations and delusions)), guided by the company to H2 2027.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| MapLight Therapeutics MPLT · Nasdaq | ML-007C-MA | Alzheimer’s disease psychosis (hallucinations and delusions) | H2 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList